PSY1 OXYCODONE-RELATED FATALITIES IN WEST VIRGINIA  by Peirce, GL et al.
A130 Abstracts
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
PSY1
OXYCODONE-RELATED FATALITIES IN WEST VIRGINIA
Peirce GL, Abate M, Smith MJ
West Virginia University, Morgantown, WV, USA
OBJECTIVES: To describe West Virginia drug-related death cases in which oxycodone
was a cause or contributor with regard to demographic characteristics, concomitant
drugs, pre-existing conditions and cause of death. METHODS: This is a cross-
sectional descriptive study that used the Forensic Drug Database, a compilation of 
case data gathered by the West Virginia Ofﬁ ce of the Chief Medical Examiner on 
drug-induced or drug-related deaths. Data were extracted for all of these death cases
between January 1, 2005 and August 18, 2007. RESULTS: There were 190 (18.3%) 
cases involving oxycodone. The majority of these decedents were male (70.5%) and 
white (96.8%), with an average age of 39.2 (10.1) years and an average BMI of 29.7 
(7.5). Approximately 84% of the oxycodone cases had at least one additional drug 
contributing to death, with diazepam (27.9%), hydrocodone (23.2%), alprazolam 
(20.0%), and ethanol (14.2%) being identiﬁ ed most commonly. Nearly two-thirds of 
cases had an existing condition considered non-contributory to death, with a history 
of substance abuse (38.4%), cardiovascular disease (32.6%), and head and central
nervous system disease (22.6%) occurring most frequently. In 92% of the oxycodone 
cases, oxycodone was considered to play a direct role in death. The manner of death 
of most oxycodone cases was classiﬁ ed as accidental (91.7%), with only 3.9% classi-
ﬁ ed as suicide. CONCLUSIONS: Concomitant drug use was a common ﬁ nding in
oxycodone-related deaths in West Virginia. This study highlights the importance of 
health care professionals talking to patients about potential dangers associated with 
combined drug misuse or abuse and to use caution when prescribing oxycodone 
with other drugs, especially controlled substances, for individuals with a history of 
substance abuse.
PSY2
HOW WELL DOES BODY MASS INDEX PREDICT WAIST
CIRCUMFERENCE FOR PATIENTS WITH METABOLIC SYNDROME?
Liu G1, Luo N2, McCollam PL3, Xie Y4
1Peking University, Beijing, China, 2National University of Singapore, Singapore, Singapore, 3Eli 
Lilly and Company, Indianapolis, IN, USA, 4University of Iowa, Iowa City, IA, USA
OBJECTIVES: To examine the association between waist circumference and body
mass index in patients with metabolic syndrome. METHODS: Based on a large elec-
tronic medical record database, all adult patients were identiﬁ ed for metabolic syn-
drome using the guidelines by the National Cholesterol Education Program Adult
Treatment Panel III (NCEP ATP III). The waist circumference (WC) was regressed as 
a linear function of body mass index (BMI) while controlling for individual age, 
gender, and identiﬁ ed latent classes of metabolic risk factors. RESULTS: A total of 
18,788 patients with metabolic syndrome were identiﬁ ed from the database. The mean 
(standard deviation) age is 57.2 (13.9), with 51.3% being females. The prevalence of 
abnormal triglycerides (TG; q150 mg/dL), high-density lipoprotein cholesterol (HDL-
C; men: 40 mg/dL; women: 50 mg/dL), blood pressure (BP; systolic q130 mmHg, 
diastolic q85 mmHg, or drug treatment for hypertension), fasting plasma glucose
(q100 mg/dL or drug treatment for diabetes mellitus), and waist circumference (WC;
men: q102 cm; women: q88 cm) was 79.6%, 74.3%, 96.4%, 69.2%, and 81.4%, 
respectively. The Pearson’s correlation between WC and BMI is 0.68. In a linear
regression model only controlling for age and gender, it is found that one unit increase 
in BMI is associated with 0.68 inches more in WC (p  0.001). BMI, age and gender
together explains 54.5% of the variation in WC. The positive relationship between 
WC and BMI still remains highly signiﬁ cant and changes little numerically, after 
including ﬁ ve latent classes of metabolic risk conditions. CONCLUSIONS: For 
patients with metabolic syndrome, there is a strong and positive association between 
waist circumference and body mass index, which remains robust after controlling for
unobserved metabolic risk conditions.
PSY3
BURDEN OF OBESITY AND ASSOCIATED TREATMENT PATTERNS IN 
EUROPE: A COMPARISON OF FIVE COUNTRIES
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany
OBJECTIVES: To assess burden of obesity and associated treatment patterns among
ﬁ ve European nations. METHODS: TNS European Healthcare Panel of individuals 
in France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess 
disease burden at national level, to build an epidemiological database in these 5 
countries. The data is representative of population gender and age strata in respective 
countries, ensured by sampling and intensive panel management. The survey collected
information on select health conditions (incl. obesity, deﬁ ned as BMI   30;
in the past 12-months), quality of life and health care-utilization. RESULTS: In
the TNS European Healthcare Panel, 8,665, 25,265, 19,887, 59,850 and
47,340 individuals completed survey in the Netherlands, Germany, Italy, France 
and U.K respectively. Prevalence of Obesity varied widely between the 5 nations, 
as follows (All, Male, Female, % individuals): Italy: 16.8%,19.1%,14.5%; 
France: 19.7%,19.4%,19.9%; Netherlands: 22.3%,18.5%,26.1%; Germany:
25.5%,24.4%,26.6%; U.K: 31.0%,29.5%,32.6%; this amounted to over 52.6 million 
individuals suffering from obesity in these 5 countries. Within each country, burden
of obesity varied by age (15–19,20–29,30–39,40–49,50–59,60–69 yrs: % individuals)
as follows: Italy: 5.1%,8.0%,13.8%,18.6%,23.6%,22.2%; France: 5.9%,9.8%,
17.3%,20.2%,27.1%,28.8%; the Netherlands: 6.5%,8.8%,21.5%,25.6%,29.8%,
28.0%; Germany: 8.3%,12.2%,22.8%,28.7%,34.2%,30.9%; U.K: 13.5%,18.0%,
28.5%,34.7%,39.4%,37.9%. Anti-obesity medications were used by 7.2%,8.0%,
10.1%,13.7%,16.1% of obese individuals in the Netherlands/Germany/U.K/France/
Italy respectively. In absolute terms, over 12.7 million individuals in the ﬁ ve countries
had taken an obesity reducing product in the last year, with France leading the list 
(3.7 million). CONCLUSIONS: Obesity disease burden appear to be substantial and
increased with age. Treatment with anti-obesity products varied across the ﬁ ve coun-
tries and did not appear to be proportional to the disease burden in the respective 
countries. Closer scrutiny is warranted to assess current practices to alleviate disease 
burden in respective geographies.
PSY4
THE USE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY
(HTRS) REGISTRY DATA TO UNDERSTAND DIFFERENCES IN
RECOMBINANT FACTOR VIIA (RFVIIA) DOSING AND CLINICAL 
OUTCOMES FOR SPECIFIC JOINT HEMORRHAGES IN HEMOPHILIA
Valentino LA1, Cooper DL2
1Rush University and Rush Children’s Hospital, Chicago, IL, USA, 2Novo Nordisk, Inc., 
Princeton, NJ, USA
OBJECTIVES: Frequent bleeding episodes within joints (hemarthrosis) in patients 
with congenital hemophilia with alloantibody inhibitors (CHwI) can result in the
development of target joints with eventual functional disability. Clinical trials have 
assessed the efﬁ cacy of rFVIIa in the treatment of hemarthroses. Such studies have not 
been designed to address whether speciﬁ c joints are more difﬁ cult to treat. The HTRS 
Registry is a collaborative effort between HTRS and Novo Nordisk to understand the 
efﬁ cacy and safety of rFVIIa and expand knowledge about treatment of hemophilia. 
METHODS: We analyzed data from 2041 rFVIIa-treated bleeds in the HTRS registry 
(January 2004-November 2008) to identify hemarthroses in patients with CHwI.
RESULTS: There were 1163 hemarthroses treated with rFVIIa (ﬁ rst line:1,065, second
line:98). Median age at time of bleed was 9 yrs (range:0–60). The 798 non-target (NT)
and 344 target (T) joint bleeds included (NT/T): ankle (279/169); elbow (202/90);
knee (143/76); shoulder (46/5); foot (45/1); wrist (43/1); hand (43/0) and hip (24/4). 
Median (range) total rFVIIa dose per treatment episode for non-target joints was
400 mcg/kg (46–18130 mcg/kg) and for target joints was 630 mcg/kg (50–21392 mcg/
kg). Total dosing varied by joint and was higher for target joints (NT/T): ankle 
(300/650); knee (360/558); elbow (490/556); hip (494/884); shoulder (720/1080). 
Overall efﬁ cacy for all joint bleeds was 90%, and for target joints was 90%. CON-
CLUSIONS: For rare disorders, such as congenital hemophilia with inhibitors, obtain-
ing evidence-based outcomes for data subsets through clinical trials is not always 
practical. The HTRS registry provides another large dataset and allows for comparison 
of clinically effective dosing regimens for treatment of non-target/target joints and
across different joints. The data shown have implications for the design of future trials 
and in the analysis of trial results to account for variability in different joint bleeds
between trial arms.
PSY5
THE USEFULNESS OF REGISTRY DATA FOR UNDERSTANDING
TREATMENT PRACTICES AND CLINICAL OUTCOMES IN HEMOPHILIA: 
THE EXPERIENCE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH
SOCIETY (HTRS) REGISTRY (2004–2008)
Kessler CM1, Gill JC2, Cooper DL3
1Georgetown University Medical Center, Washington, DC, USA, 2Medical College of 
Wisconsin, Milwaukee, WI, USA, 3Novo Nordisk, Inc., Princeton, NJ, USA
OBJECTIVES: This study evaluates the HTRS registry, developed as a collaboration
to support the society research and a company post-marketing surveillance require-
ment for recombinant FVIIa in patients with congential hemophilia (CH) with allo-
antibody inhibitors (CHwI). METHODS: The HTRS registry is a web-based second 
generation database. After IRB approval and informed consents, 83 sites participated 
in the registry from January 2004 to November 2008. RESULTS: There are 2484 
patients registered including 1696 with congenital hemophilia A or B. Median age
was 13 years (range:0–85) for CH and 12 years (range:0–83) for CHwI. Non-Hispanic 
whites (CH:68%,CHwI:57%) and non-Hispanic blacks (CH:16%, CHwI:23%) were
the largest racial/ethnic groups. The majority had little or no functional limitations
(CH:77%, CHwI:66%). For CHwI patients, the median highest anti-VIII titers were
48BU (human) and 16BU (porcine). There were 6,517 acute bleeds captured
(CHwI:6,025, rFVIIa:2,207). Acute bleed data was available for 429 CHwI patients, 
including 2,041 rFVIIa-treated bleeding episodes (ﬁ rst line:1851, second line:190). 
Approximately, 57% were spontaneous, 30% traumatic, 3% surgical, and 2% dental 
procedures. Bleeds were most frequent in joints (57%, 1163 bleeds), including ankle
(448), knee (219) and elbow (292) bleeds. Others included muscle (20%), mucosal
(7%), subcutaneous (6%), and head (3%). Median (range) total rFVIIa dose per
treatment episode was 450 mcg/kg (46–43200 mcg/kg), with initial dose of 120 mcg/
kg (37–400 mcg/kg), and 3 injections (1–480) over 1 day (1–99). Overall efﬁ cacy was
90%. Adverse events were rare. CONCLUSIONS: For rare disorders, such as hemo-
philia complicated by alloantibody inhibitors, obtaining evidence-based outcomes
through clinical trials is not always practical or statistically conclusive. The analysis 
of the signiﬁ cant amount of data accumulated over a 4-year period in the HTRS
database represents an alternative approach to understanding the safety and efﬁ cacy
of new therapeutic agents through the analysis of the “collective” experience of 
patients included in a longitudinal database.
